Trials / Completed
CompletedNCT00820404
Study Evaluating Single Doses of BLI-489 in Healthy Subjects
Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 20 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, and tolerability of single doses of BLI-489 administered intravenously in healthy subjects, and also how the drug is absorbed and eliminated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BLI-489 | |
| DRUG | Placebo |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2009-01-12
- Last updated
- 2009-07-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00820404. Inclusion in this directory is not an endorsement.